Our August edition of the life sciences review ‘The Biotech Feast - after the party comes the hangover’ warned that those at the top of the life sciences tree were showing signs of calling the end of a valuation bubble, and that we had seen something of a hiatus in deal activity particularly in terms of licensing deals. What we could not foresee however was the proximity and ferocity of the impending ‘correction’. Indeed the story of the quarter can be seen in the sector charts, with the life sc ....
16 Oct 2015
Life Sciences Review - Hair of the dog anybody?
OptiBiotix Health PLC (OPTI:LON), 18.0 | Benchmark Holdings Plc (BMK:LON), 43.2 | RUA Life Sciences Plc (RUA:LON), 11.5 | Alliance Pharma plc (APH:LON), 36.8 | Genedrive Plc (GDR:LON), 5.9 | Sphere Medical Holding (SPHR:LON), 0 | Realm Therapeutics (RLM:LON), 0 | Abaco Capital (ABA:LON), 0 | ReNeuron Group plc (RENE:LON), 3.0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Life Sciences Review - Hair of the dog anybody?
OptiBiotix Health PLC (OPTI:LON), 18.0 | Benchmark Holdings Plc (BMK:LON), 43.2 | RUA Life Sciences Plc (RUA:LON), 11.5 | Alliance Pharma plc (APH:LON), 36.8 | Genedrive Plc (GDR:LON), 5.9 | Sphere Medical Holding (SPHR:LON), 0 | Realm Therapeutics (RLM:LON), 0 | Abaco Capital (ABA:LON), 0 | ReNeuron Group plc (RENE:LON), 3.0
- Published:
16 Oct 2015 -
Author:
Derren Nathan -
Pages:
8
Our August edition of the life sciences review ‘The Biotech Feast - after the party comes the hangover’ warned that those at the top of the life sciences tree were showing signs of calling the end of a valuation bubble, and that we had seen something of a hiatus in deal activity particularly in terms of licensing deals. What we could not foresee however was the proximity and ferocity of the impending ‘correction’. Indeed the story of the quarter can be seen in the sector charts, with the life sc ....